Information Provided By:
Fly News Breaks for April 12, 2018
TXMD
Apr 12, 2018 | 08:21 EDT
Jefferies analyst Matthew Andrews believes label negotiations with the FDA on TX-004 is incrementally positive for TherapeuticsMD. The company is one step closer to approval after a tough 2017, Andrews tells investors in a research note. Amid the potential for two FDA approvals in 2018, no near-term financing overhang and potential for stronger than expected TX-004 launch, shares of TherapeuticsMD are undervalued, the analyst contends. He keeps a Buy rating on the stock with a $15 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD